STAT reports that Flagship is investing £100 million to establish ‘AI-native platform companies’ in the UK, targeting advances in human and planetary health. The initiative aims to create biotech firms that use artificial intelligence at their core.
This move signals growing interest in AI-driven approaches within the biotech sector. For pharma and biotech executives, it may mean increased competition and new opportunities for collaboration or investment as AI becomes more central to research and development.